Skip to main content
Sunshine Biopharma Inc. logo

Sunshine Biopharma Inc. — Investor Relations & Filings

Ticker · SBFM ISIN · US8677817004 LEI · 5299005Y64EHRQDQ2Q25 US Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2022-03-18 Regulatory Filings
Country US United States of America
Listing US SBFM

About Sunshine Biopharma Inc.

https://www.sunshinebiopharma.com/

Sunshine Biopharma Inc. is a pharmaceutical company engaged in the research, development, and commercialization of life-saving medicines. The company's primary focus is on various therapeutic areas, with a significant emphasis on oncology and antiviral treatments.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2022
Regulatory Filings
2022-03-18 English
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the U.S. SEC, dated March 10, 2022, by Sunshine Biopharma, Inc. It reports the entry into a material definitive agreement related to a private placement of common stock and warrants, including details of the securities sold, pricing, and registration rights. The document also includes information about the closing of the private placement and related press releases. There are no financial statements or quarterly/annual financial results presented, nor is this a transcript, proxy, or governance report. The content focuses on financing activities, specifically a private placement and related securities issuance. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive details about the financing transaction, not just an announcement or a brief notice, so it is not an RPA or RNS. Confidence is high due to the clear description of a financing transaction and related agreements.
2022-03-14 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the U.S. SEC, which is a current report used to announce major events that shareholders should know about. The content includes the entry into a material definitive agreement (a research agreement with the University of Arizona), redemption of preferred stock shares by the CEO, and a press release about the research agreement. There are no financial statements or detailed financial data presented, nor is this an earnings release or annual/interim report. The document is primarily an announcement of corporate events and agreements, typical of an 8-K filing. Given the nature of the content and the form type, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-02-25 English
Director's Dealing 2022
Director's Dealing
2022-02-22 English
Director's Dealing 2022
Director's Dealing
2022-02-18 English
Director's Dealing 2022
Director's Dealing
2022-02-18 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.